Literature DB >> 17948903

Is HMGB1 an osteocyte alarmin?

Joseph P Bidwell1, Jieping Yang, Alexander G Robling.   

Abstract

The death of osteocytes, the terminally differentiated cells of the osteoblast lineage that are embedded in bone and regulate remodeling, is significant to both normal and pathological bone resorption. Apoptotic osteocytes putatively release a clarion signal that enhances the development of the bone-resorbing osteoclasts and targets their migration to the breach in the osteocyte network. This phenomenon is thought to underlie normal repair of bone microdamage and contribute to the etiologies of inflammatory bone loss. The chromatin protein high mobility group box 1 protein (HMGB1) has been identified as an "alarmin" in other tissues. An alarmin is an endogenous molecule released by dead and dying cells that alert the innate immune system to damage and the need for tissue repair. Wang and colleagues presented evidence in a landmark 1999 study showing that released HMGB1 is a lethal mediator of sepsis. Extracellular HMGB1 is a ligand for the toll-like receptors (TLRs) and for the receptor for advanced glycation end products (RAGE) all of which amplify inflammation. Recent studies by our lab and others have shown that HMGB1 is a bone-active cytokine. It is released by apoptotic osteoblasts in vitro, including the MLO-Y4 osteocyte-like cells. Extracellular HMGB1 enhances the expression of RANKL, TNFalpha, and IL6 in osteoblastogenic bone marrow stromal cell cultures, and it is chemotactic to osteoclasts. In this prospectus we will review HMGB1 activity at the immune-bone interface and propose a role for HMGB1 as an osteocyte alarmin and mediator of normal remodeling and inflammatory bone loss.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17948903     DOI: 10.1002/jcb.21572

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  23 in total

Review 1.  The danger from within: alarmins in arthritis.

Authors:  Meriam Nefla; Dirk Holzinger; Francis Berenbaum; Claire Jacques
Journal:  Nat Rev Rheumatol       Date:  2016-10-13       Impact factor: 20.543

Review 2.  The Role of Osteocytes in Age-Related Bone Loss.

Authors:  Robert L Jilka; Charles A O'Brien
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

3.  Innate immunity sensors participating in pathophysiology of joint diseases: a brief overview.

Authors:  Jiri Gallo; Milan Raska; Yrjo T Konttinen; Christophe Nich; Stuart B Goodman
Journal:  J Long Term Eff Med Implants       Date:  2014

4.  Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice.

Authors:  Hannah M Davis; Alyson L Essex; Sinai Valdez; Padmini J Deosthale; Mohammad W Aref; Matthew R Allen; Andrea Bonetto; Lilian I Plotkin
Journal:  Bone       Date:  2019-04-24       Impact factor: 4.398

Review 5.  Inflammation in osteoarthritis: is it time to dampen the alarm(in) in this debilitating disease?

Authors:  M H J van den Bosch
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

Review 6.  Osteocyte apoptosis.

Authors:  Robert L Jilka; Brendon Noble; Robert S Weinstein
Journal:  Bone       Date:  2012-12-11       Impact factor: 4.398

7.  RAGE supports parathyroid hormone-induced gains in femoral trabecular bone.

Authors:  Binu K Philip; Paul J Childress; Alexander G Robling; Aaron Heller; Peter P Nawroth; Angelika Bierhaus; Joseph P Bidwell
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-22       Impact factor: 4.310

Review 8.  Osteocytes: master orchestrators of bone.

Authors:  Mitchell B Schaffler; Wing-Yee Cheung; Robert Majeska; Oran Kennedy
Journal:  Calcif Tissue Int       Date:  2013-09-17       Impact factor: 4.333

9.  Nmp4/CIZ: road block at the intersection of PTH and load.

Authors:  Paul Childress; Alexander G Robling; Joseph P Bidwell
Journal:  Bone       Date:  2009-09-18       Impact factor: 4.398

Review 10.  RAGE Signaling in Skeletal Biology.

Authors:  Lilian I Plotkin; Alyson L Essex; Hannah M Davis
Journal:  Curr Osteoporos Rep       Date:  2019-02       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.